Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials
Naunyn-Schmiedeberg's Archives of Pharmacology · 17.08.2026
DOI: 10.1007/s00210-026-05809-5 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 17.08.2026. Verfasst von Bilal Wazir Khan und 13 weiteren Autor:innen. Beteiligte Einrichtung: Khyber Medical College, Peshawar, Pakistan. bilal.wazir@kmc.edu.pk. Die Arbeit nennt 50 Literaturangaben.
Abstract (Originalsprache)
To evaluate the efficacy and safety of CagriSema, a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a Glucagon-Like Peptide-1 (GLP-1) receptor agonist, compared with placebo, cagrilintide, or semaglutide monotherapy in overweight or obese individuals. A systematic review and meta-analysis was conducted in accordance with PRISMA and Cochrane guidelines. Seven randomized controlled trials (RCTs) (n = 8,069) were included. Pooled analyses were performed using random-effects models, including subgrouping based on type 2 diabetes status. Risk of bias was assessed with RoB 2, and certainty of evidence was graded with GRADE. CagriSema produced significantly greater weight loss than semaglutide (MD = -7.58 kg; 95% CI = -10.30 to -4.86; p < 0.00001), cagrilintide (MD -9.24 kg; 95% CI -10.46 to -8.02, p < 0.00001), and placebo (MD = -13.99 kg; 95% CI = -18.38 to -9.61; p < 0.00001). Glycemic outcomes were heterogeneous, but lipid parameters improved versus placebo. Adverse events were primarily gastrointestinal and injection-site reactions, with no increase in serious adverse events. CagriSema provides substantial and clinically meaningful weight reduction with a favorable safety profile. Importantly, it demonstrates superior efficacy to both cagrilintide and semaglutide, highlighting its therapeutic potential. Future large-scale trials are required to confirm long-term safety and durability, especially given its clear advantage over semaglutide in reducing body weight.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Khyber Medical College, Peshawar, Pakistan. bilal.wazir@kmc.edu.pk.
- Rawalpindi Medical University, Rawalpindi, Pakistan.
- Spinghar Institute of Higher Education, Kabul, Afghanistan.
- Khyber Medical College, Peshawar, Pakistan.
- Islamabad Medical and Dental College, Islamabad, Pakistan.
- Dow University of Health Sciences, Karachi, Pakistan.
Zitieren
APA
Khan, B. W., Agha, S. A., Qamar, I., Khattak, M. H., Rehman, A., Qazi, T. I., Siddiqui, S. A., Zeeshan, N., Khan, U. Z., Bibi, H., Khan, M. F., Khan, H. W., Mian, A. M., & Rafay, M. A. (2026). Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-026-05809-5
Vancouver
Khan BW, Agha SA, Qamar I, Khattak MH, Rehman A, Qazi TI, et al. Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-026-05809-5
BibTeX
@article{Khan2026,
author = {Khan, Bilal Wazir and Agha, Syed AsadUllah and Qamar, Ihsan and Khattak, Muhammad Huzaifa and Rehman, Amna and Qazi, Tayyaba Ikram and Siddiqui, Shahreena Athar and Zeeshan, Nafila and Khan, Umer Zaryab and Bibi, Humaira and Khan, Muhammad Faaz and Khan, Haris Wazir and Mian, Affan Masaud and Rafay, Muhammad Abdur},
title = {Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2026},
doi = {10.1007/s00210-026-05809-5}
}
EUVIMED